Clinical Trial Update: The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating inhaled PUL-042 for rhinovirus-induced symptoms in smokers with COPD (GOLD stage 0) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PUL-042

Snippet

Sponsor: Pulmotect, Inc. | Conditions: COPD | Phase 2 | Status: COMPLETED